REMS Safety Update on BLENREP

December 2, 2021

ASCO has been notified of a recent safety notice relating to BLENREP (belantamab mafodotin - blmf) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program. A REMS Letter for Professional Societies has been released to address the potential risk of ocular adverse events associated with BLENREP in Relapsed/Refractory Multiple Myeloma (RRMM) patients, and to provide education on management of ocular toxicity in this patient population. More information for healthcare providers can be found on the BLENREP REMS website for healthcare professionals.